Evogene Stock Is Estimated To Be Significantly Overvalued

Retrieved on: 2021-04-18 04:07:30

Tags for this article:

Click the tags to see associated articles and topics

Evogene Stock Is Estimated To Be Significantly Overvalued. View article details on hiswai:

Excerpt

Evogene has a cash-to-debt ratio of 19.77, which ranks in the middle range of the companies in Biotechnology industry. Based on this, GuruFocus ...

Article found on: www.gurufocus.com